Enterprise Value
3.076M
Cash
23.44M
Avg Qtr Burn
-5.562M
Short % of Float
0.71%
Insider Ownership
5.95%
Institutional Own.
8.56%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Allocetra (Immunotherapy) Details Treatment of organ failure associated with Sepsis, Organ failure | Phase 2b Update | |
Allocetra (Immunotherapy) Details Osteoarthritis, Knee osteoarthritis | Phase 1/2 Data readout | |
Allocetra (Immunotherapy) Details Osteoarthritis, Basal thumb osteoarthritis | Phase 1/2 Data readout | |
Allocetra (Immunotherapy) Details Osteoarthritis, Knee osteoarthritis | Phase 1/2 Data readout | |
Allocetra (Immunotherapy) +/_ anti-PD1 checkpoint inhibitors Details Solid tumor/s, Cancer | Failed Discontinued | |
Tovinontrine (IMR-687) Details Sickle cell disease, Genetic disorder, Blood disorder | Failed Discontinued | |
Allocetra (Immunotherapy) Details Bone marrow transplantation, Prevention of post-bone marrow transplantations complications | Failed Discontinued | |
Tovinontrine (IMR-687) Details Beta thalessemia, Genetic disorder | Failed Discontinued | |
Allocetra (Immunotherapy) + Chemotherapy Details Solid tumor/s, Cancer | Failed Discontinued | |
Allocetra (Immunotherapy) Details COVID-19, Non-alcoholic steatohepatitis , Liver disease | Failed Discontinued |